AMMO sees 2022 revenue $190M, two est. $183.01M » 08:5305/1105/11/21
AMMO is pleased to…
AMMO is pleased to provide updated 2022 Fiscal Year revenue guidance for its fiscal year ending March 31, 2022 of $190 million following the successful closing of the GunBroker.com transaction. In addition to the forecasted 206% growth in revenue, the Company projects Adjusted EBITDA to surpass $65 million.
|Over a week ago|
AMMO, Mill City Ventures III partner on GunBroker.com customer financing » 08:4205/0605/06/21
AMMO is pleased to…
AMMO is pleased to announce that it has entered into a non-binding Letter of Intent with Mill City Ventures III, a non-bank lender and specialty finance company, whereby the two companies will work together to provide GunBroker.com customers with the option to purchase items through the GunBroker.com website using short-term consumer financing provided by Mill City.
Vivos Therapeutics files to sell 2.96M shares of common stock » 17:3505/0305/03/21
Roth Capital Partners is…
Roth Capital Partners is acting as sole book running manager. Co-managers include National Securities Corporation and Craig-Hallum.
Revive Therapeutics enters into research agreement with UCSF for Bucillamine » 09:2205/0305/03/21
Revive Therapeutics announces that it has entered into a sponsored research agreement with University of California, San Francisco, or UCSF, to explore the utility of Bucillamine as a treatment for severe COVID-19. The agreement will support research in the laboratory of Dr. John Fahy to test the efficacy of Bucillamine in pre-clinical models of COVID-19 and to design protocols that test the utility of Bucillamine in human trials. Dr. Fahy is the senior author of a recent study, titled "Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry" showing that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. These findings uncovered a vulnerability of SARS-CoV-2 to thiol-based drugs and provide rationale to test thiol-based drugs such as Bucillamine as novel treatments for COVID-19. The company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 at this time.
AMMO closes acquisition of GunBroker.com » 08:4205/0305/03/21
AMMO is pleased to…
AMMO is pleased to announce the closing of the previously announced acquisition of the GunBroker.com business, the world's largest on-line auction marketplace dedicated to firearms, hunting, shooting and related products. The Transaction involved an approximate $240 million merger of reorganized entities resulting in GunBroker.com and certain affiliates becoming a wholly owned subsidiary of AMMO. The Company anticipates issuing post-Transaction updated guidance on Tuesday, May 11, 2021.
Vivos Therapeutics files to sell 9.71M shares of common stock for holders 17:3104/2704/27/21
Revive Therapeutics files for orphan drug designation for psilocybin » 09:1904/2704/27/21
Revive Therapeutics is…
Revive Therapeutics is pleased to announce it has filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for Psilocybin to treat moderate to severe traumatic brain injury.
Fly Intel: Top five analyst initiations » 09:5204/2204/22/21
DRIO, OKTA, PINS, POWW, NOVN
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DarioHealth (DRIO) initiated with an Outperform at Cowen. 2. Okta (OKTA) initiated with an Outperform at Raymond James. 3. Pinterest (PINS) initiated with a Buy at LightShed Partners. 4. AMMO (POWW) initiated with a Buy at Lake Street. 5. Novan (NOVN) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMMO initiated with a Buy at Lake Street » 08:4904/2204/22/21
Lake Street analyst Mark…
Lake Street analyst Mark Smith initiated coverage of AMMO with a Buy rating and $9 price target. The producer of ammunition and brass casings is "disrupting a mature industry," rapidly growing sales and taking market share through new product launches, strong partnerships, and innovative acquisitions, Smith tells investors. A large backlog of orders shows strong demand for ammunition and provides a foundation for growth he expects to continue "well into" fiscal year 2022, Smith added.
Revive Therapeutics announces research results for oral thin film psilocybin » 08:4904/2204/22/21
Revive Therapeutics is…
Revive Therapeutics is pleased to announce the completion of the research results and filing of a U.S. provisional patent application with The United States Patent and Trademark Office on an oral thin-film delivery system with psilocybin developed under a research partnership agreement with Reed Research Group at the University of Wisconsin-Madison. This novel OTF offers a unique delivery of psilocybin as a potential treatment option for mental illness, neurological and substance abuse disorders. The objective of the Research study determined that psilocybin could be incorporated into chitosan-tannin composite hydrogel solutions, cast into molds, form stable flexible thin films after drying, and release psilocybin upon dissolution in water. University of Wisconsin-Madison's Reed Research Group successfully demonstrated that psilocybin can be incorporated into chitosan-tannin hydrogel solutions, cast into molds, and dried to create a flexible thin film. The OTF psilocybin product dissolved in water with dosage forms ranging between 1 mg and 20 mg. Revive is in discussion with a leading OTF contract manufacturer to assist in the clinical scale-up and manufacturing of the OTF psilocybin product. Future studies with the OTF psilocybin product will include evaluation in humans under U.S. Food and Drug Administration Phase I and II clinical studies as a potential treatment in various mental illness, neurological and substance abuse disorders. As a result of the Research study, the Wisconsin Alumni Research Foundation, the technology transfer office for the University of Wisconsin-Madison, submitted a provisional patent application to the UPTSO, entitled "Composite Chitosan-Tannin-Active Agent Compositions and Methods of Making and Using Same". At a high level, the provisional patent application describes tannin-chitosan composite OTF incorporating active pharmaceutical ingredients, such as psilocybin.